Andrew Huberman· PhD
mortality was double in people who were receiving the drug, the trial was not the the powered to detect mortality as a primary outcome.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
mortality was double in people who were receiving the drug, the trial was not the the powered to detect mortality as a primary outcome.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Turns out uh many more people developed uh heart failure and like adverse events uh under the drug. So they stopped the trial